Is Kestra Medical Technologies (KMTS) A Bargain Or Already Fully Priced?

Kestra Medical Technologies (KMTS) drew fresh attention after recent share price moves, with the stock closing at $28.76 on 24 October 2026, and posting varied returns over the past month and the past three months.

For context, Kestra Medical Technologies has seen a 26.0% 90-day share price return and a 17.9% year-to-date share price return, while the 1-year total shareholder return sits at 10.6%. This points to momentum that has been stronger in the short term than over the full year as investors react to recent updates and reassess both growth potential and risk.

Scan how Kestra Medical Technologies stacks up against other potential opportunities by reviewing a curated set of 21 high quality undiscovered gems in the market today.

The recent climb in Kestra Medical Technologies mirrors growing interest, yet sentiment can run ahead of reality. To see whether the latest move matches the fundamentals, the valuation picture now matters most.

Most Popular Narrative: 4% Undervalued

Kestra Medical Technologies is trading at a last close of $28.76 against a widely followed fair value estimate of $30.00. This frames the recent share move against a slightly higher narrative-based valuation anchored on detailed growth and profitability assumptions using a 7.52% discount rate.

Category underpenetration in the U.S., where management estimates only 1 in 7 of roughly 850,000 eligible patients is currently prescribed a wearable defibrillator, continues to offer a long runway for adoption that can support prescription growth and higher revenue.

Large scale real world evidence from ACE PAS and related publications, including data on low false alarms, high wear time and successful arrhythmia conversion, is helping reposition WCDs in clinician thinking and can support broader prescribing behavior that lifts volumes and revenue visibility.

See why 1 investors see Kestra Medical Technologies as 4% undervalued.

Result: Fair Value of $30 (UNDERVALUED)

Still, the Kestra Medical Technologies story leans heavily on rapid prescription growth and improving margins, and any setback on either front could quickly challenge this undervalued thesis.

Find out about the key risks to this Kestra Medical Technologies narrative.

Another View on Kestra Medical Technologies

The fair value work around $30 for Kestra Medical Technologies leans on growth and margin assumptions, yet the current P/S ratio of 16.1x tells a tougher story. That is far above the US Medical Equipment industry at 2.7x and a fair ratio estimate of 4.2x, which points to meaningful valuation risk if expectations ease.

Investors are left weighing which signal matters more in practice: the narrative based fair value, or a sales multiple that already prices in a lot of future progress, and which one to trust when conditions inevitably change. See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Mixed messages around Kestra Medical Technologies can be confusing. Move quickly, review the underlying data, and pressure test both the risks and rewards yourself with 1 key reward and 3 important warning signs

Looking for more investment ideas beyond Kestra Medical Technologies?

If Kestra Medical Technologies has sharpened your focus, do not stop here. Use the tools at your fingertips to line up your next moves with confidence.

• Target resilient opportunities that still look mispriced by checking a curated set of 29 high quality undervalued stocks before other investors focus on them.
• Prioritise staying power over drama by reviewing a list of solid balance sheet and fundamentals (24 results) that can better handle tough conditions without constant refinancing worries.
• Control risk while staying invested by scanning 30 resilient stocks with low risk scores that score well on stability instead of relying only on gut feel or headlines.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com